Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 151 | Tiburio Therapeutics | Series A | $31.0M | Cambridge, United States |
| 152 | Quentis Therapeutics | Grant | $1.0M | New York, United States |
| 153 | Rodeo Therapeutics | Series Unknown | $8.9M | Seattle, United States |
| 154 | MouSensor | Seed | $3.3M | New York, United States |
| 155 | System1 Biosciences | Series A | $25.0M | San Francisco, United States |
| 156 | Nohla Therapeutics | Series B | $11.0M | Seattle, United States |
| 157 | Cydan | Series Unknown | $34.0M | Cambridge, United States |
Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.
Quentis Therapeutics is a developer of immuno-therapeutics designed to address ER stress in multiple diseases.
Rodeo Therapeutics is a developer of small-molecule therapies designed to promote regeneration and repair of multiple tissue types.
MouSensor is an early-stage biotech company.
System1 Biosciences is a neurotherapeutics company.
Nohla Therapeutics is a biotechnology company that develops a shelf alternative to bone marrow transplants.
Cydan is an orphan drug accelerator focused on identifying and de-risking compounds with therapeutic and commercial potential.
Alexandria Venture Investments has invested in 157 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Alexandria Venture Investments's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Pharmaceutical. The firm invests across 7 different industry categories.
Among tracked funding rounds, Cydan received $34.0M in a Series Unknown round. Alexandria Venture Investments's total known invested capital is $3.8B.
Alexandria Venture Investments's average investment size is $37.7M across its portfolio of 157 companies.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors